Evidence map›Paper›PMID 29933702›Full record

ReviewExpert opinion on drug discovery2018

Developments with investigating descriptors for antimicrobial AApeptides and their derivatives.

Olapeju Bolarinwa, Jianfeng Cai

Abstract readReview
In one paragraph

Review in Expert opinion on drug discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. From screening to treatment:Microbiology spectrum · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olapeju Bolarinwaa Department of Chemistry , University of South Florida , Tampa , FL , USA.
Jianfeng Caia Department of Chemistry , University of South Florida , Tampa , FL , USA.

Funding

Requesting HPLC for the project of "Alpha-AApeptides as a Novel Class of Antimicrobial Biomaterials"R01GM112652 · NIGMS · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG · 2015 to 2019
$1.5M
NIGMS NIH HHS R01 GM112652
6 · The paper itself

Abstract

introductionThe development of multidrug-resistant strains of bacteria resulting from prolonged treatment with conventional antibiotics has necessitated the need for continuous research for better antibiotic strategies. One of these alternatives is evolutionary antimicrobial peptides also known as host-defense peptides (HDPs). HDPs are an integral part of the innate defense system in multicellular eukaryotes. Although HDPs can largely circumvent the persistent problem of antibiotic resistance due to their bacteriolytic membrane mechanism, they have some drawbacks including a low activity profile and protease instability. AApeptides have recently been introduced as a new class of peptidomimetics with resistance to proteolysis, improved activity profile, and limitless possibilities for structural diversity. Furthermore, they have shown excellent antimicrobial activity. Areas covered: This review updates the reader on the latest developments of antimicrobial AApeptides, the various derivatizations, and their development for antimicrobial applications. The most recent findings on the heterogeneous γ-AA backbone are also outlined. Expert opinion: AApeptides have found diverse applications in antimicrobial studies. AApeptides are believed to exhibit bactericidal properties by imitating the membranolytic action of HDPs. They have shown broad-spectrum antimicrobial activity and are active against medicinally relevant drug-resistant pathogens. AApeptides and their derivatives could gain therapeutic relevance in the design and development of antibiotic agents.

Indexed as

AnimalsAnti-Bacterial AgentsBacterial InfectionsDrug DesignDrug DevelopmentDrug Resistance, Multiple, BacterialHumansPeptidesPeptidomimeticsAnti-Bacterial AgentsPeptidesPeptidomimeticsAApeptidesantibiotic resistanceantimicrobial activityantimicrobial peptidesantimicrobial peptidomimeticshost-defense peptides (HDPs)

Identifiers

PMID29933702
PMCPMC6301047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.